EDIT Editas Sotuvning sof marjinal rentabelligi

Editas Medicine Inc - EDIT emitenti grafik logotipi

Editas Medicine, Inc. (EDIT) irsiy patologiyalarni DNK darajasida tuzatuvchi CRISPR terapiyalarini yaratish uchun genetiklarning elita jamoasini ilg'or tadqiqotlar va ishlanmalar (R&D) bilan birlashtiradi. Sof foyda marjasi biznesning samaradorlik dinamikasini aks ettiradi, bunda -145.00 joriy metrika darajasi vazifasini o'taydi. Avtomatlashtirilgan laboratoriyalarning joriy etilishi gen mahsulotlarining ishlab chiqilishini tezlashtirmoqda va innovatsiyalarning bozorga chiqish yo'lini optimallashtirmoqda.

Editas Corp (EDIT) Sotuvning sof rentabelligi: 04.07.2022 - 20.11.2026 davri uchun

Editas (EDIT) - koʻrsatkichlar kesimi va moliyaviy hisobotlar

- aksiya kursi va ekspertlarning narx prognozi:
Kompaniyaning barcha koʻrsatkichlari tahlili:Editas Medicine, Inc.
Editas Medicine Inc tayyor mahsulotlari

Aktivning investitsiya ishonchliligini baholash, daromadning vaqtincha ko'tarilishlari uchun ortiqcha to'lov qilishdan qochish maqsadida ob'ektiv rentabellik tahlilini talab qiladi. Sof foydaning tushumga nisbati daromadning har bir birligining samaradorligini belgilaydi, bu esa Editas Medicine, Inc. (EDIT) uchun yuqori malakali biologlar shtatining saqlanish xarajatlarini aks ettiradi; natijada, sof foyda marjasi kompaniyaning ilmiy patentlarni moliyaviy barqarorlikka aylantirish qobiliyatini namoyish etadi.

Muhim raqobatchilar

TEM: Sotuvning sof marjinal rentabelligi|Sof foyda bo'yicha marjinallik Qiagen QGEN|IONS (Isis Pharmaceuticals) - Sotuvning sof marjinal rentabelligi|Repligen Inc. - Sof foyda marjasi|Sotuvning sof marjinal rentabelligi RNA|CRSP - Sof marja|GeneDx - Sof foyda bo'yicha sotuv rentabelligi|Sof foyda normasi RARE|Beam Tx - Sotuvning sof marjinal rentabelligi|SRPT - Sotuvning sof marjinal rentabelligi|TWST (Twist Bio) - Sof foyda bo'yicha sotuv rentabelligi|Sotuvning sof rentabelligi TXG|Sof foyda bo'yicha sotuv rentabelligi NTLA|Stoke Therapeutics Inc (STOK) - Kompaniya sotuv marjasi|Sotuvning sof marjinal rentabelligi BLFS|Sof marja WVE (Wave Life Sciences Corp)|Sof marja Maze Therapeutics MAZE|Sof foyda normasi SION|PRME - Sof marja|Kompaniya sotuv marjasi Taysha TSHA|QURE: Sotuvning sof marjinal rentabelligi|Sof foyda bo'yicha sotuv rentabelligi MeiraGTx PLC|RGNX (REGENXBIO Inc) - Sotuvning sof marjinal rentabelligi|solidbio.com (SLDB) - Kompaniya sotuv marjasi|Sof marja Ocugen Corp (OCGN)|Pacific Biosciences of California, Inc. - Sotuvning sof rentabelligi|Benitec Biopharma - Sof foyda bo'yicha sotuv rentabelligi|DSGN: Sotuvning sof rentabelligi|RCKT: Sof foyda bo'yicha sotuv rentabelligi|FDMT - Sotuvning sof marjinal rentabelligi|LXEO: Sotuvning sof marjinal rentabelligi|Korro Bio Inc. - Sof foyda normasi|Sof marja Silence Therapeutics Inc.|Sotuvning sof rentabelligi PRQR (proqr.com)|Sof marja Codexis Bio (CDXS)|Sotuvning sof marjinal rentabelligi sangamo.com (SGMO)|Sof marja nautilus.bio NAUT|Kompaniya sotuv marjasi Metagenomi, Inc (MGX)|Precision BioSciences Inc. - Sotuvning sof marjinal rentabelligi|GBIO - Sotuvning sof marjinal rentabelligi|BOLD: Sotuvning sof marjinal rentabelligi|Sotuvning sof rentabelligi XCUR|Sof marja Imunon|Phio Pharmaceuticals - Sof foyda marjasi|Sof marja Mustang Bio, Inc. (MBIO)|Kompaniya sotuv marjasi TransCode Therapeutics, Inc.|Sof marja Bionano Genomics BNGO|Sof foyda normasi APDN|BLUE - Sof marja|Sof foyda marjasi IPA|Omega Therapeutics, Inc. (OMGA) - Sof marja|Singular Genomics Corp (OMIC) - Sotuvning sof marjinal rentabelligi|RGLS (Regulus Therapeutics, Inc.) - Sotuvning sof marjinal rentabelligi|SYRS: Sof foyda normasi|Sof foyda bo'yicha sotuv rentabelligi TBIO (Telesis Bio Inc.)|Sotuvning sof marjinal rentabelligi TRACON Pharmaceuticals Inc. (TCON)|Sof marja Unity Bio UBX